Abstract: The present invention is directed to thioether-piperidinyl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the thioether-piperidinyl compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Abstract: A subframe data generation unit determines a distribution color which is a color of a variable color subframe, and then selects pixels sequentially to perform processing on the selected pixel. Distributed brightness is calculated based on brightness and the distribution color, and a distribution ratio is set to a value of 1 at which color breakup is the smallest. An evaluation value related to a color difference when a line of sight moves is calculated based on brightness of the selected brightness of neighboring and selected pixels, and the distribution color. The distribution ratio is decreased in steps until the maximum value of the evaluation value is less than or equal to a threshold value. The brightness of three colors is converted to brightness of four colors based on the distribution color and the distribution ratio determined for each pixel.

Abstract: A dry powder inhaler is provided herein which includes a dose chamber having a staging area configured to accommodate an inhalable dose of active pharmaceutical agent. A nozzle is provided having a discharge aperture with an inhalation channel communicating the staging area with the discharge aperture. The inhalation channel is configured such that sufficient negative pressure applied to the discharge aperture draws a dose from the staging area towards the discharge aperture. An arrangement is provided for evaluating the level of depletion of a dose from the staging area. Advantageously, the subject invention allows for evaluating physical depletion of a staged dose so as to recognize the level of delivery thereof.

Abstract: In a display device 10, light-emitting subframe periods are selected such that one or more light-emitting subframe periods and one or more non-light-emitting subframe periods differ between light-emitting patterns A to D corresponding to pixels A to D. In the light-emitting pattern A, selection is made such that the number of light-emitting subframe periods is largest, in the light-emitting pattern B, selection is made such that light-emitting subframe periods differ from those in the light-emitting pattern A as much as possible, and in the light-emitting patterns C and D, selection is made such that only the longest light-emitting subframe periods in the light-emitting patterns A and B differ. Hence, a spatial location of the occurrence of contouring can be distributed, suppressing contouring. By this, a display device using a time division gray scale system is provided that can represent high gray scale and that sufficiently suppresses the occurrence of contouring.

Abstract: Interference is mitigated by effective knowledge and/or effective information about an interference signal. A higher layer in which a base station apparatus configures first interference information used for the terminal apparatus to mitigate interference from a cell-specific reference signal and/or second interference information used for the terminal apparatus to mitigate interference at least from a downlink shared channel; and a signal detection unit configured to mitigate the interference from the cell-specific reference signal based on the first interference information and to mitigate the interference at least from the downlink shared channel based on the second interference information.

Abstract: The present invention includes a human LAG3 functional assay using a Jurkat T-cell lymphoma cell line engineered to overexpress LAG3 at an optimal level relative to CD3. The assay is useful, for example, for determining the immunostimulatory properties of LAG3 modulators (e.g., inhibitors or activators). The optimized LAG3/CD3 ratio ensures expression of optimal receptor components on the T-cell and, thus, superior assay sensitivity. Immunostimulation of the T-cells can be measured, for example, by following cytokine (e.g., IL-2) production. The optimized T-cell line forms part of the present invention along with compositions generated with use of the assay.

Abstract: The present invention relates generally to the use of gene mutations, whose presence or absence are useful for predicting a patient's response to treatment with an anti-proliferative agent, in particular a WEE1 inhibitor. The presence or absence of a mutation to the TP53 gene, can be used to predict response to treatment with a WEE1 inhibitor in a patient presenting with a cancerous condition.

Abstract: A semiconductor laser element is provided with: a substrate formed of a semiconductor; a semiconductor laminated film, which is laminated on the substrate, and which includes an active layer; a first electrode and a second electrode, which are provided on surfaces parallel to the active layer on the side where the semiconductor laminated film is formed on the substrate; and a facet protection film that is provided on both the facets, which are perpendicular to the active layer, and which face each other. In the semiconductor laser element, the facet is used as a fixing surface for the semiconductor laser element, said facet having the facet protection film formed thereon.

Abstract: There is provided a particle detector that can increase a detection sensitivity to fluorescence emitted from biogenic particles. A particle detector for detecting biogenic particles includes a substrate having a principal surface and configured to collect the biogenic particles on the principal surface, a light emitting element configured to irradiate particles collected on the principal surface with excitation light, and a light receiving element configured to receive fluorescence emitted from the particles when the particles are irradiated with the excitation light from the light emitting element. An optical axis of the Fresnel lens and a ray direction of the excitation light intersect with each other. The principal surface is a mirror surface.

Abstract: The present invention provides a liquid crystal display having the advantage of higher resolution and lower power consumption while having high transmittance. The present invention is a liquid crystal display provided with a first substrate, a second substrate and a horizontal orientation-type liquid crystal layer. The first substrate includes a plurality of source bus lines, a plurality of gate bus lines, a pixel electrode, a first common electrode, a first interlayer insulation film on the plurality of source bus lines, a first conductive layer on the first interlayer insulation film, a second interlayer insulation film on the first conductive layer and a second conductive layer on the second interlayer insulation film. The first common electrode includes a plurality of first linear portions having a linear shape. The pixel electrode includes one or more second linear portions. The plurality of first linear portions and one or more second linear portions are alternately disposed.

Abstract: A semiconductor device (101) includes a plurality of pixel regions Pix arranged in a matrix having a row direction and a column direction, wherein each of the plurality of pixel regions Pix includes a thin film transistor (10) which includes a gate electrode (2), a gate insulating layer (5) covering the gate electrode, an oxide semiconductor layer (7A) provided on the gate insulating layer, and a source electrode (9s) and a drain electrode (9d) which are electrically connected to the oxide semiconductor layer, a metal oxide layer (7B) formed out of a same oxide film as the oxide semiconductor layer, an interlayer insulating layer (13) covering the thin film transistor and the metal oxide layer, and a pixel electrode (15) provided on the interlayer insulating layer and electrically connected to the drain electrode, the metal oxide layer (7B) includes a conductor region (70c), and the pixel electrode (15) overlaps with at least a part of the conductor region (70c) with the interlayer insulating layer (13) inter

Abstract: The vapor deposition apparatus employs scanning vapor deposition, and includes a limiting component including a first plate portion; a second plate portion provided with a space from the first plate portion; and a joint portion combining the first plate portion with the second plate portion, the first plate portion being provided with an first opening, the second plate portion being provided with an second opening that faces the first opening, the vapor deposition apparatus including a first space between the first opening and the second opening, the vapor deposition apparatus including a second space between the first plate portion and the second plate portion, the first space being connected to the second space, the vapor deposition apparatus including a third space that is in the outside of the limiting component, the second space being connected to the third space.

Abstract: The light-emitting device (100) includes a substrate (101) and a plurality of light-emitting sections. A first light-emitting section is made up of LED chips (102) and a first fluorescent-substance-containing resin layer (107), and a second light-emitting section is made up of LED chips (102) and a second fluorescent-substance-containing resin layer (108). The first fluorescent-substance-containing resin layer (107) and the second fluorescent-substance-containing resin layer (108) are provided in a plurality of locations such that the fluorescent-substance-containing resin layers for the different light-emitting sections are adjacently arranged.

Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Abstract: A system for image processing that matches a model image with an input image. The matching process includes using a feature location index for the model image.

Abstract: Provided is a display device capable of switching a refresh rate while suppressing deterioration in display quality and degradation in liquid crystal. In the case of switching the refresh rate from 60 Hz to 7.5 Hz, a transition period for gradually changing the refresh rate from 60 Hz to 7.5 Hz is provided between a 60-Hz period and a 7.5-Hz period. This transition period is configured by sequentially arraying a 30-Hz period, a 20-Hz period, a 15-Hz period, a 12-Hz period and a 10-Hz period from a start point of the transition period. Hence the refresh rate gradually changes from 60 Hz to 7.5 Hz sequentially through 30 Hz, 20 Hz, 15 Hz, 12 Hz and 10 Hz. The number of positive-polarity frames and the number of negative-polarity frames are respectively 20 in the whole of the transition period, and are equal to each other.

Abstract: A semiconductor device 1 according to the present invention includes a first electrode G (g1) formed on a substrate B, a first insulation film GI to cover the first electrode g1, a semiconductor film SF including a channel CH, an etching stopper film ES, and a second electrode S (s3). The semiconductor film SF is formed on the first insulation film GI with overlapping the first electrode g1 so that an edge portion SF1 thereof projects outwardly from the first electrode g1 in a plan view. The etching stopper film ES is formed of an insulation film and formed on the semiconductor film SF and the first insulation film GI to cover the channel CH. The etching stopper film ES includes a hole H (hd) in which the edge portion SF1 of the semiconductor film SF is and through which a surface of a portion of the semiconductor film SF near the channel CH is exposed in a plan view.

Abstract: The present invention is directed to compounds and pharmaceutical formulations comprising these compounds which are useful as O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors, and thus may be useful for the treatment of certain disorders such as Alzheimer's disease including reducing NFTs and/or hyperphosphorylated tau. The invention is also directed to use of the compounds as O-GlcNAcase imaging agents.

Abstract: The present invention provides a liquid crystal display device by which it is possible to attain both high transmittance and wide viewing angle even if the pixels are small.

Abstract: A pulse generation circuit is configured with a plurality of transistors of a single conductivity type. The pulse generation circuit includes: an output unit including a current limiting element configured to supply, by a predetermined current, a first voltage from a first power supply line supplied with the first voltage to an output terminal, the output unit being configured to perform a bootstrap operation that outputs the first voltage to the output terminal in response to a received input signal; and an output control unit configured to initiate the bootstrap operation when the output terminal transitions to the first voltage, and after the output terminal transitions to the first voltage, terminate the bootstrap operation and perform control so as to output the first voltage from the current limiting element to the output terminal.